EF Hutton Starts Anixa Biosciences (ANIX) at Buy

EF Hutton analyst Jason Kolbert initiates coverage on Anixa Biosciences (NASDAQ: ANIX) with a Buy rating and a price target of $10.00.

The analyst comments "Anixa Biosciences, Inc. is a biotechnology company that harnesses the immune system to fight cancer. Its lead program involves developing a CAR-T therapy targeting solid tumors, in this case, ovarian cancer. It is currently in early clinical trials. The company is also developing cancer vaccines, including one for triple-negative breast cancer and another for ovarian cancer. Anixa's innovative approach targets specific proteins, such as alpha-lactalbumin and AMHR2-ED, to trigger the immune system to prevent cancer formation. We are initiating coverage with a Buy rating and a $10.00 price target."

For an analyst ratings summary and ratings history on Anixa Biosciences click here. For more ratings news on Anixa Biosciences click here.

Shares of Anixa Biosciences closed at $3.20 yesterday.

You May Also Be Interested In

• Wells Fargo Starts Vivmark Residential (VMRK) at Overweight, 'Setting the mark for growth'
• enVVeno Medical (NVNO) files $100M mixed shelf
• DA Davidson Starts Comfort Systems USA (FIX) at Buy